Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
SK Biopharmaceuticals Launches Joint Venture with Eurofarma for AI-based Epilepsy Management Platform 2025-10-21 09:20
NSG Bio Launches NSG BioSuites at Geneo - A New Product, Largest Site, and Fourth Location in Singapore 2025-10-21 08:00
LabConnect Featured in Season Finale of Emmy-Nominated Series Tomorrow's World Today 2025-10-21 01:11
Benchling Partners with Anthropic to Build a Bridge Between Science and AI 2025-10-21 00:00
Exploring the Next Era of Cell & Gene Therapy with Nobel Laureate in London 2025-10-20 19:43
HanchorBio Showcases Pipeline Momentum with HCB101 and HCB301 Data Across Five Major Oncology Meetings in Q4 2025 2025-10-20 19:00
Groundbreaking Study in the Journal of Clinical Investigation Advances Cell Therapy for Huntington's Disease Treatment 2025-10-20 18:13
The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC 2025-10-20 17:06
Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO 2025-10-20 13:59
Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM 2025-10-20 10:36
Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability 2025-10-20 09:00
Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity 2025-10-20 08:10
Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances 2025-10-20 07:00
Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO 2025-10-18 22:46
SCG announces presentation of clinical results of SCG142 in patients with HPV-related carcinoma at ESMO 2025 2025-10-18 13:00
Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR Wild-type Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting 2025-10-17 22:00
Kelun-Biotech's Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC 2025-10-17 20:22
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences 2025-10-17 15:21
FDA approves expanded pediatric indications for YUFLYMA® (adalimumab-aaty) and unbranded adalimumab-aaty in the United States 2025-10-17 13:32
Unixell Biotech reported a case study of UX-DA001, an iPSC-derived autologous cell therapy for Parkinson Diseases at MDS Congress 2025 2025-10-16 20:35